A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (ReACT)
This study has been completed.
First Posted: December 23, 2011
Last Update Posted: April 7, 2017
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||May 17, 2016|
|Primary Completion Date:||April 2015 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Submission:||April 6, 2017|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Gatson NT, Weathers SP, de Groot JF. ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma. CNS Oncol. 2016;5(1):11-26. doi: 10.2217/cns.15.38. Epub 2015 Dec 15. Retraction in: CNS Oncol. 2016;5(2):110.
Retraction in: CNS Oncol. 2016;5(2):110